World's Best Scientists 2026 revealed!
Award Badge
Medicine
Spain
2023

D-Index & Metrics

Medicine

D-Index
118
Citations
68114
World Ranking
3990
National Ranking
2179

Research.com Recognitions

  • 2023 - Research.com Medicine in Spain Leader Award

Overview

Manuel Hidalgo is affiliated with Cornell University in the United States and has a substantial research profile in medicine, with a focus on oncology and molecular biology. Their work primarily addresses pancreatic and hepatic oncology, cancer genomics and diagnostics, and cancer immunotherapy and biomarkers.

The scientist's main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these fields, Hidalgo has contributed significantly to subfields such as:

  • Oncology
  • Cancer Research
  • Molecular Biology
  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Their research topics often cover:

  • Pancreatic and Hepatic Oncology Research
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Cancer Research and Treatments
  • Cancer Cells and Metastasis
  • Advanced Breast Cancer Therapies
  • COVID-19 and healthcare impacts

Manuel Hidalgo has published in various notable journals, with frequent appearances in:

  • Journal of Clinical Oncology
  • Cancer Research
  • Clinical Cancer Research
  • Enfermedades Infecciosas y Microbiología Clínica
  • Cancer Cell

Some recent papers include:

  • "BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial" (2020) in Nature Medicine
  • "Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy" (2021) in Cell
  • "CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma" (2020) in Cancer Cell
  • "COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study" (2020) in Journal of Clinical Oncology
  • "PDX-derived organoids model in vivo drug response and secrete biomarkers" (2020) in JCI Insight

Frequent co-authors collaborating with Hidalgo are:

  • Bruno Bockorny
  • Teresa Macarulla
  • Senthil K. Muthuswamy
  • Joseph E. Grossman
  • Jaime Feliú

Best Publications

  • Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

    Daniel D. Von Hoff;Thomas Ervin;Francis P. Arena;E. Gabriela Chiorean

  • Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

    Siân Jones;Xiaosong Zhang;D. Williams Parsons;D. Williams Parsons;Jimmy Cheng Ho Lin

  • Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

    David M. Hyman;Igor Puzanov;Vivek Subbiah;Jason E. Faris

  • Patient-derived xenograft models: an emerging platform for translational cancer research.

    Manuel Hidalgo;Frederic Amant;Andrew V. Biankin;Eva Budinská

  • Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

    Shirin Khambata-Ford;Christopher R. Garrett;Neal J. Meropol;Mark Basik

  • Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

    Manuel Hidalgo;Lillian L. Siu;John Nemunaitis;Jinee Rizzo

  • Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

    Daniel D. Von Hoff;Ramesh K. Ramanathan;Mitesh J. Borad;Daniel A. Laheru

  • Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

    Denis Soulieres;Neil N. Senzer;Everett E. Vokes;Manuel Hidalgo

  • Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

    Michael B. Atkins;Manuel Hidalgo;Walter M. Stadler;Theodore F. Logan

  • DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer

    Christine A. Iacobuzio-Donahue;Baojin Fu;Shinichi Yachida;Mingde Luo

  • Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy

    Manuel Hidalgo;S. Gail Eckhardt

  • Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

    Evanthia Galanis;Jan C. Buckner;Matthew J. Maurer;Jeffrey I. Kreisberg

  • The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

    Manuel Hidalgo;Eric K Rowinsky

  • Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment

    Viktor Grünwald;Manuel Hidalgo

  • Interrogating open issues in cancer precision medicine with patient-derived xenografts

    Annette T. Byrne;Denis G. Alférez;Frédéric Amant;Daniela Annibali

  • Pancreatic cancer: From state-of-the-art treatments to promising novel therapies

    Ignacio Garrido-Laguna;Manuel Hidalgo

  • Addressing the challenges of pancreatic cancer: future directions for improving outcomes

    Manuel Hidalgo;Stefano Cascinu;Jörg Kleeff;Roberto Labianca

  • Matrix metalloproteinase-2 contributes to cancer cell migration on collagen.

    Xiaoping Xu;Yao Wang;Zhihua Chen;Mark D. Sternlicht

  • Prognostic Significance of Tumorigenic Cells With Mesenchymal Features in Pancreatic Adenocarcinoma

    Zeshaan A. Rasheed;Jie Yang;Qiuju Wang;Jeanne Kowalski

  • Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity

    Linda A. deGraffenried;William E. Friedrichs;Douglas H. Russell;Elissa J. Donzis

Frequent Co-Authors

Antonio Jimeno
Antonio Jimeno University of Colorado Boulder
Anirban Maitra
Anirban Maitra The University of Texas MD Anderson Cancer Center
Wells A. Messersmith
Wells A. Messersmith University of Colorado Boulder
Daniel D. Von Hoff
Daniel D. Von Hoff Translational Genomics Research Institute
Ross C. Donehower
Ross C. Donehower Johns Hopkins University
Sharyn D. Baker
Sharyn D. Baker The Ohio State University
Alfredo Carrato
Alfredo Carrato University of Alcalá
Aik Choon Tan
Aik Choon Tan University of Utah
Francisco X. Real
Francisco X. Real Pompeu Fabra University
Aldo Scarpa
Aldo Scarpa University of Verona

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in Medicine but want more flexibility, there are several affordable online nursing degrees that may interest you. Online programs can help you balance your studies with work or personal responsibilities while preparing for a rewarding healthcare career.

For students seeking entry into nursing, some of the cheapest bsn programs online offer a cost-effective route toward becoming a registered nurse. Already an RN? The cheapest bsn programs allow current nurses to upgrade their credentials and boost their career opportunities.

Aspiring advanced practitioners can explore the cheapest online np programs, which train nurses to become nurse practitioners—a growing field with strong demand. For those interested in leadership, research, or academic roles, online nursing doctoral programs provide flexible doctoral options.

These online pathways can help launch or advance your healthcare career, often at a fraction of the cost and time of traditional programs.

Best Scientists Citing Manuel Hidalgo

Trending Scientists